- Home
- BJDX vs BDRX Comparison
BJDX vs BDRX Comparison
Compare BJDX & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJDX | BDRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BJDX | BDRX |
|---|---|---|
| Price | $1.74 | $3.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.7K | ★ 193.7K |
| Earning Date | 05-12-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.60 |
| 52 Week High | $4.17 | $11.88 |
Technical Indicators
Market Signals| Indicator | BJDX | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 51.78 |
| Support Level | $1.42 | $2.94 |
| Resistance Level | $2.10 | $4.39 |
| Average True Range (ATR) | 0.12 | 0.38 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 7.32 | 24.15 |
Price Performance
Historical ComparisonAbout BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.